TBI Fundamental Analysis - TRUEBLUE INC

Fundamental Rating

Taking everything into account, TBI scores 3 out of 10 in our fundamental rating. TBI was compared to 87 industry peers in the Professional Services industry. TBI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. TBI has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

TBI had negative earnings in the past year.

TBI had a negative operating cash flow in the past year.

The reported net income has been mixed in the past 5 years: TBI reported negative net income in multiple years.

TBI had a positive operating cash flow in 4 of the past 5 years.

1.2 Ratios

TBI's Return On Assets of -4.07% is on the low side compared to the rest of the industry. TBI is outperformed by 67.82% of its industry peers.

TBI has a Return On Equity of -9.24%. This is in the lower half of the industry: TBI underperforms 66.67% of its industry peers.

		Industry Rank	Sector Rank
ROA	-4.07%
ROE	-9.24%
ROIC	N/A

ROA(3y)-4.7%

ROA(5y)-4.52%

ROE(3y)-10.14%

ROE(5y)-10.07%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

TBI has a worse Gross Margin (24.02%) than 68.97% of its industry peers.

In the last couple of years the Gross Margin of TBI has remained more or less at the same level.

TBI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	24.02%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.19%

GM growth 5Y-0.39%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

TBI does not have a ROIC to compare to the WACC, probably because it is not profitable.

TBI has less shares outstanding than it did 1 year ago.

Compared to 5 years ago, TBI has less shares outstanding

The debt/assets ratio for TBI is higher compared to a year ago.

2.2 Solvency

TBI has an Altman-Z score of 3.30. This indicates that TBI is financially healthy and has little risk of bankruptcy at the moment.

The Altman-Z score of TBI (3.30) is better than 63.22% of its industry peers.

TBI has a Debt/Equity ratio of 0.22. This is a healthy value indicating a solid balance between debt and equity.

TBI has a Debt to Equity ratio of 0.22. This is comparable to the rest of the industry: TBI outperforms 55.17% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.22
Debt/FCF	N/A
Altman-Z	3.3

ROIC/WACCN/A

WACC9.15%

2.3 Liquidity

A Current Ratio of 2.01 indicates that TBI has no problem at all paying its short term obligations.

With a decent Current ratio value of 2.01, TBI is doing good in the industry, outperforming 74.71% of the companies in the same industry.

A Quick Ratio of 2.01 indicates that TBI has no problem at all paying its short term obligations.

TBI has a better Quick ratio (2.01) than 77.01% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.01
Quick Ratio	2.01

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for TBI have decreased strongly by -31.43% in the last year.

Looking at the last year, TBI shows a decrease in Revenue. The Revenue has decreased by -5.37% in the last year.

TBI shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -7.93% yearly.

EPS 1Y (TTM)-31.43%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%127.27%

Revenue 1Y (TTM)-5.37%

Revenue growth 3Y-10.33%

Revenue growth 5Y-7.93%

Sales Q2Q%12.79%

3.2 Future

The Earnings Per Share is expected to grow by 58.41% on average over the next years. This is a very strong growth

TBI is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.38% yearly.

EPS Next Y-14.47%

EPS Next 2Y60.97%

EPS Next 3Y58.41%

EPS Next 5YN/A

Revenue Next Year2.84%

Revenue Next 2Y3.94%

Revenue Next 3Y3.38%

Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TBI. In the last year negative earnings were reported.

TBI is valuated rather expensively with a Price/Forward Earnings ratio of 18.16.

The rest of the industry has a similar Price/Forward Earnings ratio as TBI.

Compared to an average S&P500 Price/Forward Earnings ratio of 23.51, TBI is valued a bit cheaper.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	18.16

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

TBI's earnings are expected to grow with 58.41% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y60.97%

EPS Next 3Y58.41%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

TBI does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

TRUEBLUE INC

NYSE:TBI (12/10/2025, 4:15:00 PM)

After market: 4.83 0 (0%)

4.83

+0.08 (+1.68%)

Chartmill FA Rating

GICS SectorIndustrials

GICS IndustryGroupCommercial & Professional Services

GICS IndustryProfessional Services

Earnings (Last)11-03 2025-11-03/amc

Earnings (Next)02-17 2026-02-17/amc

Inst Owners97.67%

Inst Owner Change3.24%

Ins Owners5.15%

Ins Owner Change-0.24%

Market Cap144.61M

Revenue(TTM)1.58B

Net Income(TTM)-28.13M

Analysts80

Price Target8.67 (79.5%)

Short Float %4.09%

Short Ratio5.03

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)82.46%

Min EPS beat(2)28.92%

Max EPS beat(2)136%

EPS beat(4)3

Avg EPS beat(4)57%

Min EPS beat(4)-24.74%

Max EPS beat(4)136%

EPS beat(8)6

Avg EPS beat(8)53.54%

EPS beat(12)8

Avg EPS beat(12)35.65%

EPS beat(16)11

Avg EPS beat(16)35.09%

Revenue beat(2)1

Avg Revenue beat(2)1.18%

Min Revenue beat(2)-2.04%

Max Revenue beat(2)4.4%

Revenue beat(4)2

Avg Revenue beat(4)0.7%

Min Revenue beat(4)-2.04%

Max Revenue beat(4)4.4%

Revenue beat(8)3

Avg Revenue beat(8)-0.22%

Revenue beat(12)3

Avg Revenue beat(12)-1.16%

Revenue beat(16)5

Avg Revenue beat(16)-0.62%

PT rev (1m)-1.92%

PT rev (3m)-1.92%

EPS NQ rev (1m)-966.6%

EPS NQ rev (3m)-242.21%

EPS NY rev (1m)0%

EPS NY rev (3m)-11.48%

Revenue NQ rev (1m)0.19%

Revenue NQ rev (3m)0.6%

Revenue NY rev (1m)1.56%

Revenue NY rev (3m)1.56%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	18.16
P/S	0.09
P/FCF	N/A
P/OCF	N/A
P/B	0.48
P/tB	0.59
EV/EBITDA	N/A

EPS(TTM)-0.46

EYN/A

EPS(NY)0.27

Fwd EY5.51%

FCF(TTM)-2.18

FCFYN/A

OCF(TTM)-1.59

OCFYN/A

SpS52.9

BVpS10.16

TBVpS8.13

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-4.07%
ROE	-9.24%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	24.02%
FCFM	N/A

ROA(3y)-4.7%

ROA(5y)-4.52%

ROE(3y)-10.14%

ROE(5y)-10.07%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.19%

GM growth 5Y-0.39%

F-Score3

Asset Turnover2.29

Health

		Industry Rank	Sector Rank
Debt/Equity	0.22
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	62.33%
Cap/Sales	1.13%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.01
Quick Ratio	2.01
Altman-Z	3.3

F-Score3

WACC9.15%

ROIC/WACCN/A

Cap/Depr(3y)102.48%

Cap/Depr(5y)103.83%

Cap/Sales(3y)1.51%

Cap/Sales(5y)1.52%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-31.43%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%127.27%

EPS Next Y-14.47%

EPS Next 2Y60.97%

EPS Next 3Y58.41%

EPS Next 5YN/A

Revenue 1Y (TTM)-5.37%

Revenue growth 3Y-10.33%

Revenue growth 5Y-7.93%

Sales Q2Q%12.79%

Revenue Next Year2.84%

Revenue Next 2Y3.94%

Revenue Next 3Y3.38%

Revenue Next 5YN/A

EBIT growth 1Y22.02%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year115.73%

EBIT Next 3Y37.45%

EBIT Next 5YN/A

FCF growth 1Y-325.72%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-179.24%

OCF growth 3YN/A

OCF growth 5YN/A

TRUEBLUE INC / TBI FAQ

Can you provide the ChartMill fundamental rating for TRUEBLUE INC?

ChartMill assigns a fundamental rating of 3 / 10 to TBI.

What is the valuation status for TBI stock?

ChartMill assigns a valuation rating of 2 / 10 to TRUEBLUE INC (TBI). This can be considered as Overvalued.

What is the profitability of TBI stock?

TRUEBLUE INC (TBI) has a profitability rating of 1 / 10.

How financially healthy is TRUEBLUE INC?

The financial health rating of TRUEBLUE INC (TBI) is 6 / 10.

Can you provide the expected EPS growth for TBI stock?

The Earnings per Share (EPS) of TRUEBLUE INC (TBI) is expected to decline by -14.47% in the next year.

TRUEBLUE INC (TBI) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

TRUEBLUE INC / TBI FAQ

Can you provide the ChartMill fundamental rating for TRUEBLUE INC?

What is the valuation status for TBI stock?

What is the profitability of TBI stock?

How financially healthy is TRUEBLUE INC?

Can you provide the expected EPS growth for TBI stock?